Cardiovascular Systems (CSII) Stock Hits New 52-Week High
Zacks Investment Research | Jan 19, 2020 09:49PM ET
Shares of Cardiovascular Systems, Inc. (NASDAQ:CSII) reached a new 52-week high of $53.71 on Jan 17, closing the session marginally lower at $53.61. The stock has rallied 2.7% since its first-quarter fiscal 2020 earnings announcement on Oct 29.
The company witnessed mixed fiscal first-quarter results, backed by strong performance in the domestic and international markets. Notably, it is concentrating on product innovation through R&D investments.
Let us delve deeper.
Q3 Performance
Cardiovascular Systems ended first-quarter fiscal 2020 on a mixed note, with wider-than-expected loss and a revenue beat. It witnessed year-over-year revenue improvements in Coronary and Peripheral device segments within the domestic market. Treatment of the first patient in the Middle East with a peripheral orbital atherectomy system is another highlight of the quarter. The FDA approval of Viperwire Advance Coronary Guide Wire with Flex Tip instills optimism.
Over and above, the company’s reaffirmed guidance for fiscal 2020 indicates that it will be able to maintain its ongoing momentum in the second quarter as well.
Other Key Drivers
Portfolio Expansion: Investors are optimistic about the impressive customer adoption of Cardiovascular Systems’ 1-millimeter Sapphire balloon, the Teleport Microcatheter and radio support. The company is increasingly focusing on improving its R&D, thus leading to product launches like that of the Nitinol Coronary ViperWire Advance wire with Flex Tip in the United States.
The launch of Nitino is a crucial addition to Cardiovascular Systems’ complex coronary portfolio, consisting of Diamondback 360 Coronary Orbital Atherectomy System with GlideAssist, the Sapphire balloon, including the only 1.0mm coronary angioplasty balloon in the U.S. market, and the Teleport microcatheter.
Notably, the company introduced Peripheral Orbital Atherectomy System With GlideAssist in Europe in December 2019.
International Business: The concerted efforts of Cardiovascular Systems to increase its global footprint buoy optimism within the investors. The company is making progress in introducing orbital atherectomy system (OAS) globally. In this respect, Cardiovascular Systems is performing robustly on its partnership with OrbusNeich, which allows OrbusNeich to distribute Cardiovascular Systems’ coronary and peripheral orbital atherectomy systems in multiple countries outside the United States and Japan.
Get The News You Want
Zacks Rank & Key Picks
Currently, Cardiovascular Systems carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Haemonetics Corporation (NYSE:HAE) , Hill-Rom Holdings, Inc. (NYSE:HRC) and Medtronic plc (NYSE:MDT) .
Haemonetics currently sports a Zacks Rank #1 (Strong Buy) and has a projected long-term earnings growth rate of 13.5%. You can see Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.